Extremities

Acumed Launches the Ulna Nail 2 System to Offer More Choice in Treating Ulna Fractures

Acumed is pleased to announce the launch of the Ulna Nail 2 System, created to treat simple, transverse, and short oblique fractures, as well as osteotomies of the ulna.

HILLSBORO, ORE. (PRWEB) MAY 20, 2022

Acumed is pleased to announce the launch of the Ulna Nail 2 System, created to treat simple, transverse, and short oblique fractures, as well as osteotomies of the ulna. The system is designed to provide a less invasive intramedullary approach to reduce soft-tissue irritation and preserve the osseous blood supply, which aids in fracture union compared to traditional open reduction internal fixation (ORIF). *

Designed in conjunction with Roy Sanders, MD, an orthopaedic surgeon in Tampa, FL, the Acumed Ulna Nail 2 is available in three diameters and seven lengths. The system offers a universal instrumentation base set, making it possible for one set to support multiple intramedullary nail families.

“The nails feature contouring to accommodate the shape of the intramedullary canal and are designed to address varying patient anatomy,” said Milton Torres, Vice President, Hand and Upper Extremity at Acumed. “Our proprietary Tip-LocTM technology achieves stabilization of the nail’s far end through a sized bushing and set screw combination, which allows for fracture rotation and length control.”

“The Ulna Nail 2 System represents an advance in intramedullary nailing of the fibula and ulna with power reamers to allow for ease of insertion,” said Dr. Sanders. “Additionally, Tip-Loc will allow surgeons to achieve a true double-locked nail, both proximal and distal to the fracture, with a sized implant that can more closely match the patient’s anatomy.”

The system also offers updated instrumentation, including carbon fiber radiolucent targeting guides to streamline the procedure, threaded holes within the nail for interlocking constructs, and low-profile, headless hexalobe screws.

“Acumed has a long history of delivering industry-first solutions designed to provide surgeons with in situ customization options to achieve optimal patient fit and restoration of function,” said Sharon Wolfington, President and CEO of Acumed. “Acumed has the most complete selection of upper extremity fixation and specialty plates on the market.** And our new Ulna Nail 2 is a minimally invasive option that enhances our industry-leading portfolio.”

About Acumed

We serve highly skilled, specialized surgeons who demand comprehensive, high-quality medical devices for patients with simple to complex injuries for optimal restoration of function.

Acumed and OsteoMed have more than three decades of experience in the orthopaedic industry, with the mission of aiding the afflicted through the ingenuity of our minds, the labor of our hands, and the compassion of our hearts. Acumed and OsteoMed have three primary campuses in Hillsboro, Oregon; Addison, Texas; and Madrid, Spain, and offices around the world. OsteoMed is a wholly owned subsidiary of Acumed. For more information, visit http://www.acumed.net.

Acumed is a Colson Medical | Marmon | Berkshire Hathaway company.

  • Lee YH, Lee SK, Chung MS, Baek GH, Gong HS, Kim KH. Interlocking contoured intramedullary nail fixation for selected diaphyseal fractures of the forearm in adults. J Bone Joint Surg Am. 2008;90:1891–1898.

**Competitive data on file with Acumed. GEN00-28-F; 2021.

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button